{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:27:09Z","timestamp":1790483229367,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.healun.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T16:00:04Z","timestamp":1475769604000},"page":"1311-1320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices"],"prefix":"10.1016","volume":"35","author":[{"given":"Sirtaz","family":"Adatya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Sunny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan J.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Colvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thennapan","family":"Thennapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Dodge Zantek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pritzker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Eckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Uriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2016.09.010_bib1","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"Slaughter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.09.010_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.healun.2013.12.001","article-title":"An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial","volume":"33","author":"Najjar","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2010.05.016","article-title":"Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation","volume":"56","author":"Uriel","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2016.09.010_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1313385","article-title":"Unexpected abrupt increase in left ventricular assist device thrombosis","volume":"370","author":"Starling","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.09.010_bib5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.jacc.2013.05.089","article-title":"Major bleeding during HeartMate II support","volume":"62","author":"Bunte","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2016.09.010_bib6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.athoracsur.2010.04.099","article-title":"Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients","volume":"90","author":"Crow","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.healun.2016.09.010_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.healun.2012.09.013","article-title":"The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary","volume":"32","author":"Feldman","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.healun.2010.02.003","article-title":"Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy","volume":"29","author":"Slaughter","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.healun.2013.11.001","article-title":"Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device","volume":"33","author":"Kirklin","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib10","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.healun.2015.06.018","article-title":"Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE Study","volume":"34","author":"Katz","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib11","doi-asserted-by":"crossref","first-page":"A16405","DOI":"10.1161\/circ.132.suppl_3.16405","article-title":"Prevention of HeartMate II pump thrombosis\u2014recommendations and preliminary observations from the PREVENT study","volume":"132","author":"Emani","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2016.09.010_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jchf.2015.01.004","article-title":"Gold standard in anticoagulation assessment of left ventricular assist\u00a0device patients? How about bronze","volume":"3","author":"Stehlik","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.healun.2016.09.010_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jchf.2014.11.009","article-title":"Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support","volume":"3","author":"Adatya","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.healun.2016.09.010_bib14","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.healun.2014.08.022","article-title":"Activated partial thromboplastin time overestimates anti-coagulation in left ventricular assist device patients","volume":"33","author":"McIlvennan","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib15","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.09.010_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1592\/phco.19.9.760.31547","article-title":"Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time","volume":"19","author":"Rosborough","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.healun.2016.09.010_bib17","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.09.010_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0002-8703(99)70118-3","article-title":"A new regimen for heparin use in acute coronary syndromes","volume":"138","author":"Hochman","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2016.09.010_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2016.09.010_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.09.010_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1650358","article-title":"The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays","volume":"75","author":"Kitchen","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.healun.2016.09.010_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ajcp\/67.5.477","article-title":"Variation among commercial activated partial thromboplastin time reagents in response to heparin","volume":"67","author":"Shapiro","year":"1977","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.healun.2016.09.010_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1160\/TH10-02-0099","article-title":"Interlaboratory variation in heparin monitoring: lessons from the Quality Management Program of Ontario coagulation surveys","volume":"104","author":"Cuker","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.healun.2016.09.010_bib24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.healun.2016.09.010_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.healun.2016.09.010_bib26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.158.10.1140","article-title":"Effect of warfarin on activated partial thromboplastin time in patients receiving heparin","volume":"158","author":"Kearon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.healun.2016.09.010_bib27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0049-3848(76)90014-1","article-title":"The anticoagulant effect of heparan sulfate and dermatan sulfate","volume":"8","author":"Teien","year":"1976","journal-title":"Thromb Res"},{"key":"10.1016\/j.healun.2016.09.010_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1309\/AJCPR3JTOK7NKDBJ","article-title":"Pathology consultation on anticoagulation monitoring: factor X-related assays","volume":"140","author":"Wool","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.healun.2016.09.010_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12185-014-1702-z","article-title":"Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin","volume":"101","author":"Mitsuguro","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.healun.2016.09.010_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-2007-1003474","article-title":"Contact factors in health and disease","volume":"13","author":"Saito","year":"1987","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.healun.2016.09.010_bib31","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","article-title":"In vivo roles of factor XII","volume":"120","author":"Renne","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.healun.2016.09.010_bib32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.healun.2016.09.010_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.thromres.2015.06.028","article-title":"The role of activated coagulation factor XII in overall clot stability and fibrinolysis","volume":"136","author":"Konings","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.healun.2016.09.010_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/joim.12430","article-title":"Factor XII: a novel target for safe prevention of thrombosis and inflammation","volume":"278","author":"Kenne","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.healun.2016.09.010_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1055\/s-0038-1642386","article-title":"The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors","volume":"71","author":"Halbmayer","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.healun.2016.09.010_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ajcp\/100.2.94","article-title":"Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time","volume":"100","author":"Burns","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.healun.2016.09.010_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.healun.2016.09.010_bib38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.100.7.736","article-title":"Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators","volume":"100","author":"Folsom","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2016.09.010_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0037-1613748","article-title":"Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response","volume":"83","author":"O\u2019Donnell","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.healun.2016.09.010_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0308-2261(21)00063-1","article-title":"The biosynthesis of factor VIII","volume":"8","author":"Bloom","year":"1979","journal-title":"Clin Haematol"},{"key":"10.1016\/j.healun.2016.09.010_bib41","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.biocel.2003.08.002","article-title":"Coagulation factor V","volume":"36","author":"Duga","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.healun.2016.09.010_bib42","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.healun.2014.01.092","article-title":"Anti-factor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin in patients with continuous flow left ventricular assist devices","volume":"33","author":"Yarmohammadi","year":"2014","journal-title":"J Hear Lung Transplant"},{"key":"10.1016\/j.healun.2016.09.010_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2257.1999.00183.x","article-title":"Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin","volume":"21","author":"Kovacs","year":"1999","journal-title":"Clin Laboratory Haematol"},{"key":"10.1016\/j.healun.2016.09.010_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00001721-200011020-00004","article-title":"Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay","volume":"11","author":"Kitchen","year":"2000","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249816303382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249816303382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:12:49Z","timestamp":1762355569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249816303382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1053249816303382"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2016.09.010","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}